Combination Intensity-Modulated Radiotherapy and Sorafenib Improves Outcomes in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis

Munire Abulimiti, Zhenyu Li, Haifeng Wang, Palida Apiziaji, Yisikandaer Abulimiti, Yao Tan, Munire Abulimiti, Zhenyu Li, Haifeng Wang, Palida Apiziaji, Yisikandaer Abulimiti, Yao Tan

Abstract

Purpose: To compare the difference in outcome of hepatocellular carcinoma (HCC) with portal vein thrombosis (PVTT) between intensity-modulated radiotherapy (IMRT) concurrent with sorafenib and IMRT alone.

Methods: A total of 82 patients with PVTT from 2014 to 2019 were included. Of these, 36 received IMRT concurrent with sorafenib treatment (group A), while 46 underwent IMRT alone (group B). The dose of IMRT was 40.0-62.5 Gy/2-2.5 Gy/4-6 w, and patients received orally administered sorafenib 400 mg twice a day in combination with IMRT. Overall survival (OS), progression-free survival (PFS), and median distant metastasis-free survival (DMFS) were evaluated by using LIFETEST procedure of SAS.

Results: The median survival time was 11.0 months in group A versus 9.0 months in group B. The 1- and 2-year OS in group A were 44.9% and 3.8% versus 28.6% and 2.6% in group B (P=0.036), respectively. The median PFS was 6.0 months in group A versus 3.0 months in group B. The 1- and 2-year PFS in group A were 20.7% and 6.9% versus 2.7% and 0.0% in group B (P=0.012), respectively. The 1- and 2-year DMFS in group A were 38.0% and 7.9% versus 16.7% and 0.0% in group B (P=0.019), respectively. Multivariate analysis showed that Child-Pugh classification, AFP response, and overall response were independent risk factors for OS (P < 0.05). There were no significant differences in adverse events except fatigue and skin reactions between the two groups.

Conclusion: Compared with IMRT alone, IMRT concurrent with sorafenib can improve the long-term efficacy of HCC patients with PVTT, without increasing adverse reactions. The patients with Child-Pugh A, overall response, and AFP response obtained better OS.

Conflict of interest statement

The authors declare that there are no conflicts of interest.

Copyright © 2021 Munire Abulimiti et al.

Figures

Figure 1
Figure 1
Comparison of LIFETEST of OS between IMRT concurrent with sorafenib (group A) and IMRT alone (group B).
Figure 2
Figure 2
Comparison of LIFETEST of PFS between IMRT concurrent with sorafenib (group A) and IMRT alone (group B).
Figure 3
Figure 3
Comparison of LIFETEST of DMFS between IMRT concurrent with sorafenib (group A) and IMRT alone (group B).

References

    1. Bray F., Ferlay J., Soerjomataram I., Siegel R. L., Torre L. A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians . 2018;68(6):394–424. doi: 10.3322/caac.21492.
    1. Chen W., Sun K., Zheng R., et al. Cancer incidence and mortality in China, 2014. Chinese Journal of Cancer Research . 2018;30(1):1–12. doi: 10.21147/j.issn.1000-9604.2018.01.01.
    1. Zhang Z.-m., Lai E. C. H., Zhang C., et al. The strategies for treating primary hepatocellular carcinoma with portal vein tumor thrombus. International Journal of Surgery . 2015;20(20):8–16. doi: 10.1016/j.ijsu.2015.05.009.
    1. Wu Y. L., Feng Q. F. Progress of surgery combined with radiotherapy for primary hepatocellular carcinoma. Chinese Journal of Radiation Medicine and Protection . 2019;39(39):554–557.
    1. Bruix J., Raoul J. L., Sherman M., et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. Journal of Hepatology . 2012;57(4):821–829. doi: 10.1016/j.jhep.2012.06.014.
    1. Kudo M., Finn R. S., Qin S., et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet (London, England) . 2018;391(10126):1163–1173. doi: 10.1016/S0140-6736(18)30207-1.
    1. Zhu K., Chen J., Lai L., et al. Hepatocellular carcinoma with portal vein tumor thrombus: treatment with transarterial chemoembolization combined with sorafenib—a retrospective controlled study. Radiology . 2014;272(1):284–293. doi: 10.1148/radiol.14131946.
    1. Giorgio A., Merola M. G., Montesarchio L., et al. Sorafenib combined with radio-frequency ablation compared with sorafenib alone in treatment of hepatocellular carcinoma invading portal vein: a western randomized controlled trial. Anticancer Research . 2016;36(11):6179–6183. doi: 10.21873/anticanres.11211.
    1. Brade A. M., Ng S., Brierley J., et al. Phase 1 trial of sorafenib and stereotactic body radiation therapy for hepatocellular carcinoma. International Journal of Radiation Oncology, Biology, Physics . 2016;94(3):580–587. doi: 10.1016/j.ijrobp.2015.11.048.
    1. Zhao Y., Zhu X., Wang H., et al. Safety and efficacy of transcatheter arterial chemoembolization plus radiotherapy combined with sorafenib in hepatocellular carcinoma showing macrovascular invasion. Frontiers in Oncology . 2019;9(9) doi: 10.3389/fonc.2019.01065.1065
    1. Shi J., Lai E. C., Li N., et al. A new classification for hepatocellular carcinoma with portal vein tumor thrombus. Journal of Hepato-Biliary-Pancreatic Sciences . 2011;18(1):74–80. doi: 10.1007/s00534-010-0314-0.
    1. Eisenhauer E. A., Therasse P., Bogaerts J., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) European Journal of Cancer (Oxford, England: 1990) . 2009;45(2):228–247. doi: 10.1016/j.ejca.2008.10.026.
    1. Gomaa A. I., Hashim M. S., Waked I. Comparing staging systems for predicting prognosis and survival in patients with hepatocellular carcinoma in Egypt. PLoS One . 2014;9(3) doi: 10.1371/journal.pone.0090929.e90929
    1. European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. Journal of Hepatology . 2018;69(1):182–236. doi: 10.1016/j.jhep.2018.03.019.
    1. Kok V. C., Chen Y. C., Chen Y. Y., et al. Sorafenib with transarterial chemoembolization achieves improved survival vs. sorafenib alone in advanced hepatocellular carcinoma: a nationwide population-based cohort study. Cancers . 2019;11(7):p. 985. doi: 10.3390/cancers11070985.
    1. Yoon S. M., Ryoo B. Y., Lee S. J., et al. Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion: a randomized clinical trial. JAMA Oncology . 2018;4(5):661–669. doi: 10.1001/jamaoncol.2017.5847.
    1. He M., Li Q., Zou R., et al. Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial. JAMA Oncology . 2019;5(7):953–960. doi: 10.1001/jamaoncol.2019.0250.
    1. He C., Peng W., Liu X., Li C., Li X., Wen T. F. Post-treatment alpha-fetoprotein response predicts prognosis of patients with hepatocellular carcinoma: a meta-analysis. Medicine . 2019;98(31) doi: 10.1097/MD.0000000000016557.e16557
    1. Chou W. C., Lee C. L., Yang T. S., et al. Changes in serum alpha-fetoprotein level predicts treatment response and survival in hepatocellular carcinoma patients and literature review. Journal of the Formosan Medical Association . 2018;117(2):153–163. doi: 10.1016/j.jfma.2017.03.010.
    1. Sánchez A. I. P., Roces L. V., García I. Z., et al. Value of alpha-fetoprotein as an early biomarker for treatment response to sorafenib therapy in advanced hepatocellular carcinoma. Oncology Letters . 2018;15(6):8863–8870. doi: 10.3892/ol.2018.8400.
    1. Wada Y., Takami Y., Matsushima H., et al. The safety and efficacy of combination therapy of sorafenib and radiotherapy for advanced hepatocellular carcinoma: a retrospective study. Internal Medicine (Tokyo, Japan) . 2018;57(10):1345–1353. doi: 10.2169/internalmedicine.9826-17.
    1. Que J., Wu H. C., Lin C. H., Huang C. I., Li L. C., Ho C. H. Comparison of stereotactic body radiation therapy with and without sorafenib as treatment for hepatocellular carcinoma with portal vein tumor thrombosis. Medicine . 2020;99(13) doi: 10.1097/MD.0000000000019660.e19660
    1. Chen B., Li Y. X., Wang W., Tan Y., Song Y. W. Efficacy and prognosis of radiotherapy for hepatocellular carcinoma with tumor thrombosis in main portal vein or/and vena cava. International Journal of Radiation Oncology, Biology, Physics . 2019;105(1):E215–E216. doi: 10.1016/j.ijrobp.2019.06.2061.
    1. Kim J. W., Kim D. Y., Han K. H., Seong J. Phase I/II trial of helical IMRT-based stereotactic body radiotherapy for hepatocellular carcinoma. Digestive and Liver Disease: Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver . 2019;51(3):445–451. doi: 10.1016/j.dld.2018.11.004.
    1. Cerrito L., Annicchiarico B. E., Iezzi R., Gasbarrini A., Pompili M., Ponziani F. R. Treatment of hepatocellular carcinoma in patients with portal vein tumor thrombosis: beyond the known frontiers. World Journal of Gastroenterology . 2019;25(31):4360–4382. doi: 10.3748/wjg.v25.i31.4360.
    1. Choi Y., Kim J. W., Cha H., Han K. H., Seong J. Overall response of both intrahepatic tumor and portal vein tumor thrombosis is a good prognostic factor for hepatocellular carcinoma patients receiving concurrent chemoradiotherapy. Journal of Radiation Research . 2014;55(1):113–120. doi: 10.1093/jrr/rrt082.
    1. Kong X. Q., Dong Y. P., Wu J. X., et al. High-biologically effective dose palliative radiotherapy for a tumor thrombus might improve the long-term prognosis of hepatocellular carcinoma: a retrospective study. Radiation Oncology (London, England) . 2017;12(1):p. 92. doi: 10.1186/s13014-017-0831-y.
    1. Chen S. W., Lin L. C., Kuo Y. C., Liang J. A., Kuo C. C., Chiou J. F. Phase 2 study of combined sorafenib and radiation therapy in patients with advanced hepatocellular carcinoma. International Journal of Radiation Oncology, Biology, Physics . 2014;88(5):1041–1047. doi: 10.1016/j.ijrobp.2014.01.017.
    1. Goody R. B., Brade A. M., Wang L., et al. Phase I trial of radiation therapy and sorafenib in unresectable liver metastases. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology . 2017;123(2):234–239. doi: 10.1016/j.radonc.2017.01.018.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera